EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 160 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Biomedical Engineering Student Invents Device for At-Home Breast Cancer Screening January 6, 2021 Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... July 6, 2022 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy? October 31, 2022 Load more HOT NEWS FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... Veteran Dresses As Captain America & Brings Joy To Children In... Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient...
